Spots Global Cancer Trial Database for Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

Official Title: Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

Study ID: NCT00575744

Conditions

Breast Cancer

Interventions

Sentinel Node Biopsy

Study Description

Brief Summary: We continue to collect information in support of the hypothesis that the histology of the first draining lymph node (sentinel node) accurately predicts the histology of the rest of the axillary lymph nodes.

Detailed Description: Using a technique combining Technetium-99 sulfur colloid and Lymphazurin Blue Dye, we have established that the sentinel node predicts the pathology results of the rest of the axillary lymph nodes. This minimally invasive technique, which can be readily performed under local anesthesia, makes the need for full axillary lymph node dissection unnecessary for most patients. If the sentinel node is negative, no further surgery is necessary. If positive, a complete axillary node dissection is performed. In addition, the injections are made while the patient is under anesthesia, reducing the physical and psychological pain that accompanies injections done pre-operatively.